Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma

Liver International

Volumn 26, Issue 5, 2006, Pages 536-542

  Akamatsu, Masatoshi ^a   Yoshida, Haruhiko ^a   Shiina, Shuichiro ^a   Teratani, Takuma ^a   Obi, Shuntaro ^a   Tateishi, Ryousuke ^a   Mine, Norio ^a   Kondo, Yuji ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon; Recurrence; Survival

Indexed keywords

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME;

AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; DRUG EVALUATION; FEMALE; HEPACIVIRUS; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33646778095     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01260.x     Document Type: Article

References (32)

1. Davila J A, Morgan R O, Shaib Y, McGlynn K A, El-Serag H B. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology 2004; 127 1372-80.
2. Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991; 67: 429-33.
3. Colombo M, Kuo G, Choo Q L, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006-8.
4. Bruix J, Barrera J M, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2: 1004-6.
5. International Interferon α/Hepatocellular Carcinoma Study Group, Brunetto M R, Oliveri F, Koehler M, et al. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998; 351: 1535-9.
6. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-81.
7. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
8. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-30.
9. Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 2004; 127: S17-26.
10. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: S159-66.
11. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306.
12. Manns M P, McHutchison J G, Gordon S C, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
13. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
14. Fried M W, Shiffman M L, Reddy K R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
15. Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
16. Simmonds P, Holmes E C, Cha T A, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993; 74: 2391-9.
17. Lau J Y, Davis G L, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
18. Okamoto H, Kurai K, Okada S, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: Comparative study of four distinct genotypes. Virology 1992; 188: 331-41.
19. Makuuchi M, Hasegawa H, Yamazaki S. Ultrasonically guided subsegmentectomy. Surg Gynecol Obstet 1985; 161: 346-50.
20. Shiina S, Yasuda H, Muto H, et al. Percutaneous ethanol injection in the treatment of liver neoplasms. Am J Roentgenol 1987; 149: 949-52.
21. Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994; 74: 817-25.
22. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: From percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62: 64-8.
23. Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000; 88: 1557-64.
24. Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
25. Koike Y, Shiratori Y, Sato S, et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216-23.
26. Yoshida H, Tateishi R, Arakawa Y, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004; 53: 425-30.
27. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-7.
28. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
29. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
30. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123: 483-91.
31. Sakon M, Umeshita K, Nagano H, et al. Clinical significance of hepatic resection in hepatocellular carcinoma: Analysis by disease-free survival curves. Arch Surg 2000; 135: 1456-9.
32. Akamatsu M, Yoshida H, Shiina S, et al. Neither hepatitis C virus genotype nor virus load affects survival of patients with hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004; 16: 459-66.